Background Clostridium difficile is the leading cause of antibiotic-associated diarrhoea, both
in healthcare facilities and in the community. The recurrence rate of C. difficile infection (CDI) …

The burden of Clostridium difficile infection (CDI) is profound and growing. CDI now
represents a common cause of health care–associated diarrhea, and is associated with …

The incidence of Clostridium difficile infection (CDI) continues to rise, whilst treatment
remains problematic due to recurrent, refractory and potentially severe nature of disease …

The current picture of Clostridium difficile infection (CDI) is alarming with a mortality rate
ranging between 3% and 15% and a CDI recurrence rate ranging from 12% to 40%. Despite …

There are only a limited number of antimicrobials for treating severe Clostridium difficile
infection (sCDI). Tigecycline shows significant in vitro effect against C. difficile and is …

Fulminant Clostridioides difficile infection (FCDI) encompasses 3 to 5% of all CDI cases with
associated mortality rates between 30 and 40%. Major treatment modalities include surgery …

Clostridioides difficile infection (CDI) is a major enteric disease associated with antibiotic
use and a leading cause of hospital-acquired infections worldwide. This is the first guideline …

Carbapenem-resistant organisms are increasingly common worldwide, particularly in India
and are associated with high mortality rates especially in patients with severe infection such …

Introduction: Tigecycline has emerged as first line therapy for serious systemic infections
due to important pathogens (except P. aeruginosa and Proteus sp.), including multi-drug …

Cancer patients frequently suffer from gastrointestinal complications. In this manuscript, we
update our 2013 guideline on the diagnosis and management of gastrointestinal …